Anti-hyperglycemic and Anti-hypercholesterolemic Effects of Aloe vera Leaf Gel in Hyperlipidemic Type 2 Diabetic Patients: A Randomized Double-Blind Placebo-Controlled Clinical Trial

被引:83
|
作者
Huseini, Hasan Fallah [1 ]
Kianbakht, Saeed [1 ]
Hajiaghaee, Reza [2 ]
Dabaghian, Fataneh Hashem [3 ]
机构
[1] ACECR, Res Inst Med Plants, Dept Pharmacol & Appl Med, Pouleh Kordan, Karaj, Iran
[2] ACECR, Res Inst Med Plants, Dept Pharmacognosy & Pharm, Pouleh Kordan, Karaj, Iran
[3] Univ Tehran Med Sci, Res Inst Islamic & Complementary Med, Tehran, Iran
关键词
Aloe vera; Liliaceae; diabetes; hyperlipidemia; patient; ANTIDIABETIC ACTIVITY; L JUICE; COMBINATION; MANAGEMENT; BENEFITS; EXTRACT; SPICES; HERBS;
D O I
10.1055/s-0031-1280474
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Diabetes mellitus type 2 with dyslipidemia is a common disease. Previous studies suggest that aloe (Aloe vera L.) leaf gel may positively affect the blood glucose and lipid levels in dyslipidemic type 2 diabetic patients. Thus, in this randomized double-blind placebo-controlled clinical trial with hyperlipidemic (hypercholesterolemic and/or hypertriglyceridemic) type 2 diabetic patients aged 40 to 60 years not using other anti-hyperlipidemic agents and resistant to daily intake of two 5 mg glyburide tablets and two 500mg metformin tablets, the efficacy and safety of taking aloe gel (one 300 mg capsule every 12 hours for 2 months) combined with the aforementioned drugs in treatment of 30 patients were evaluated and compared with the placebo group (n = 30). The aloe gel lowered the fasting blood glucose, HbA1c, total cholesterol, and LDL levels significantly (p = 0.036, p = 0.036, p = 0.006, and p = 0.004, respectively) without any significant effects on the other blood lipid levels and liver/kidney function tests (p > 0.05) compared with the placebo at the endpoint. No adverse effects were reported. The results suggest that aloe gel may be a safe anti-hyperglycemic and anti-hypercholesterolemic agent for hyperlipidemic type 2 diabetic patients.
引用
下载
收藏
页码:311 / 316
页数:6
相关论文
共 50 条
  • [21] Effects of Semelil (ANGIPARS™) on diabetic peripheral neuropathy: A randomized, double-blind Placebo-controlled clinical trial
    Bakhshayeshi, S.
    Madani, S. P.
    Hemmatabadi, M.
    Heshmat, R.
    Larijani, B.
    DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 19 (01) : 65 - 70
  • [22] A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFECT OF ENALAPRIL IN PATIENTS WITH CLINICAL DIABETIC NEPHROPATHY
    BAUER, JH
    REAMS, GP
    HEWETT, J
    KLACHKO, D
    MESSINA, C
    KNAUS, V
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1992, 20 (05) : 443 - 457
  • [23] A Randomized, Double-Blind, Placebo-Controlled Trial of Spironolactone on Diastolic Dysfunction in Diabetic Patients
    Morales, Helia
    Espinoza, Francisco
    Larrea, Ricardo
    Gonzalez, Bernardita
    Puga, Luz
    Vukusich, Antonio
    Marusic, Elisa T.
    DIABETES, 2011, 60 : A562 - A562
  • [24] Creatine in Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
    Gualano, Bruno
    Painneli, Vitor De Salles
    Roschel, Hamilton
    Artioli, Guilherme Giannini
    Neves, Manoel, Jr.
    De Sa Pinto, Ana Lucia
    Rossi Da Silva, Maria Elizabeth
    Cunha, Maria Rosaria
    Garcia Otaduy, Maria Concepcion
    Leite, Claudia Da Costa
    Ferreira, Julio Cesar
    Pereira, Rosa Maria
    Brum, Patricia Chakur
    Bonfa, Eloisa
    Lancha, Antonio Herbert, Jr.
    MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2011, 43 (05): : 770 - 778
  • [25] Anti-hyperglycemic effects of propolis or metformin in type 2 Diabetes Mellitus A randomized controlled trial
    Ochoa-Morales, Paola D.
    Gonzalez-Ortiz, Manuel
    Martinez-Abundis, Esperanza
    Perez-Rubio, Karina G.
    Patino-Laguna, Anayeli D. J.
    INTERNATIONAL JOURNAL FOR VITAMIN AND NUTRITION RESEARCH, 2023, 93 (06) : 498 - 506
  • [26] Creatine supplementation does not impair kidney function in type 2 diabetic patients: a randomized, double-blind, placebo-controlled, clinical trial
    Bruno Gualano
    Vitor de Salles Painelli
    Hamilton Roschel
    Rebeca Lugaresi
    Egidio Dorea
    Guilherme Giannini Artioli
    Fernanda Rodrigues Lima
    Maria Elizabeth Rossi da Silva
    Maria Rosária Cunha
    Antonio Carlos Seguro
    Maria Heloisa Shimizu
    Maria Concepción García Otaduy
    Marcelo Tatit Sapienza
    Cláudia da Costa Leite
    Eloisa Bonfá
    Antonio Herbert Lancha Junior
    European Journal of Applied Physiology, 2011, 111 : 749 - 756
  • [27] Creatine supplementation does not impair kidney function in type 2 diabetic patients: a randomized, double-blind, placebo-controlled, clinical trial
    Gualano, Bruno
    Painelli, Vitor de Salles
    Roschel, Hamilton
    Lugaresi, Rebeca
    Dorea, Egidio
    Artioli, Guilherme Giannini
    Lima, Fernanda Rodrigues
    Rossi da Silva, Maria Elizabeth
    Cunha, Maria Rosaria
    Seguro, Antonio Carlos
    Shimizu, Maria Heloisa
    Garcia Otaduy, Maria Concepcion
    Sapienza, Marcelo Tatit
    Leite, Claudia da Costa
    Bonfa, Eloisa
    Lancha Junior, Antonio Herbert
    EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY, 2011, 111 (05) : 749 - 756
  • [28] The effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial
    Seyyedebrahimi, ShadiSadat
    Khodabandehloo, Hadi
    Esfahani, Ensieh Nasli
    Meshkani, Reza
    ACTA DIABETOLOGICA, 2018, 55 (04) : 341 - 353
  • [29] The effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial
    ShadiSadat Seyyedebrahimi
    Hadi Khodabandehloo
    Ensieh Nasli Esfahani
    Reza Meshkani
    Acta Diabetologica, 2018, 55 : 341 - 353
  • [30] Effects of broccoli sprout with high sulforaphane concentration on inflammatory markers in type 2 diabetic patients: A randomized double-blind placebo-controlled clinical trial
    Mirmiran, Parvin
    Bahadoran, Zahra
    Hosseinpanah, Farhad
    Keyzad, Amitis
    Azizi, Fereidoun
    JOURNAL OF FUNCTIONAL FOODS, 2012, 4 (04) : 837 - 841